Y MAbs Financials
YMAB Stock | USD 10.01 0.27 2.63% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0077 | 0.0089 |
|
| |||||
Current Ratio | 10.07 | 5.5202 |
|
|
Investors should never underestimate Y MAbs' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Y MAbs' cash flow, debt, and profitability to make informed and accurate decisions about investing in Y mAbs Therapeutics.
Net Income |
|
YMAB | Select Account or Indicator |
Understanding current and past Y MAbs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Y MAbs' financial statements are interrelated, with each one affecting the others. For example, an increase in Y MAbs' assets may result in an increase in income on the income statement.
Y mAbs Therapeutics Earnings Geography
Please note, the presentation of Y MAbs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Y MAbs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Y MAbs' management manipulating its earnings.
Y MAbs Stock Summary
Y MAbs competes with Revolution Medicines, Black Diamond, Passage Bio, Bluebird Bio, and Mersana Therapeutics. Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US9842411095 |
CUSIP | 984241109 |
Location | New York; U.S.A |
Business Address | 230 Park Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ymabs.com |
Phone | 646 885 8505 |
Currency | USD - US Dollar |
Y MAbs Key Financial Ratios
Return On Equity | -0.25 | ||||
Profit Margin | (0.28) % | ||||
Operating Margin | (0.43) % | ||||
Price To Sales | 5.45 X | ||||
Revenue | 84.82 M |
Y MAbs Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 216.4M | 132.0M | 212.8M | 141.5M | 127.9M | 150.1M | |
Other Current Liab | 4.6M | 6.2M | 10.8M | 12.4M | 12.3M | 7.2M | |
Other Liab | 2.2M | 4.7M | 3.0M | 3.1M | 3.5M | 3.0M | |
Net Tangible Assets | 198.9M | 105.8M | 178.4M | 106.2M | 122.2M | 129.5M | |
Net Debt | (204.9M) | (110.7M) | (177.9M) | (104.0M) | (77.2M) | (81.1M) | |
Retained Earnings | (165.9M) | (285.2M) | (340.5M) | (436.0M) | (457.5M) | (434.6M) | |
Accounts Payable | 8.5M | 9.4M | 13.6M | 14.2M | 6.1M | 9.0M | |
Cash | 207.1M | 114.6M | 181.6M | 105.8M | 78.6M | 129.7M | |
Capital Surpluse | 225.4M | 364.7M | 391.6M | 519.2M | 597.1M | 304.2M | |
Other Current Assets | 4.8M | 7.7M | 7.5M | 5.5M | 5.0M | 4.9M | |
Total Liab | 17.5M | 26.2M | 32.7M | 32.2M | 26.9M | 22.3M | |
Total Current Assets | 212.0M | 122.4M | 202.3M | 130.4M | 111.1M | 142.8M | |
Other Assets | 370K | 7.9M | 206.9M | 5.7M | 1.0 | 0.95 | |
Net Invested Capital | 198.9M | 105.8M | 180.1M | 109.2M | 101.0M | 104.9M | |
Net Working Capital | 198.4M | 102.8M | 174.4M | 102.2M | 91.0M | 102.2M |
Y MAbs Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 2.0M | 598K | 1.9M | 757K | 870.6K | 821.4K | |
Gross Profit | (166K) | 18.5M | 32.4M | 57.7M | 73.4M | 77.1M | |
Operating Income | (83.0M) | (119.9M) | (115.4M) | (94.8M) | (25.7M) | (27.0M) | |
Ebit | (83.0M) | (119.9M) | (115.4M) | (94.8M) | (26.4M) | (27.7M) | |
Research Development | 63.5M | 93.7M | 93.2M | 91.6M | 54.2M | 63.1M | |
Ebitda | (82.8M) | (119.5M) | (114.7M) | (94.0M) | (25.7M) | (27.0M) | |
Cost Of Revenue | 166K | 2.2M | 2.5M | 7.6M | 11.4M | 12.0M | |
Income Before Tax | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (20.9M) | (21.9M) | |
Net Income | (78.9M) | (118.3M) | (56.3M) | (96.3M) | (21.4M) | (22.5M) | |
Income Tax Expense | (2.1M) | (994K) | 1.1M | 757K | 561K | 589.1K | |
Net Interest Income | 2.0M | 598K | (1.9M) | (757K) | 4.7M | 4.9M |
Y MAbs Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 59.3M | (92.5M) | 66.9M | (75.8M) | (27.1M) | (25.8M) | |
Free Cash Flow | (75.5M) | (91.4M) | (103.5M) | (75.9M) | (27.2M) | (28.6M) | |
Depreciation | 166K | 396K | 782K | 839K | 735K | 409.2K | |
Other Non Cash Items | 43K | 8.7M | (62.0M) | 3.6M | (1.3M) | (1.3M) | |
Net Income | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (21.4M) | (22.5M) | |
End Period Cash Flow | 207.1M | 114.6M | 181.6M | 105.8M | 78.6M | 129.7M | |
Change To Netincome | 4.7M | 22.9M | (40.8M) | 29.2M | 33.6M | 35.2M |
YMAB Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Y MAbs's current stock value. Our valuation model uses many indicators to compare Y MAbs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Y MAbs competition to find correlations between indicators driving Y MAbs's intrinsic value. More Info.Y mAbs Therapeutics is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, Y MAbs' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Y MAbs' earnings, one of the primary drivers of an investment's value.Y MAbs' Earnings Breakdown by Geography
Y mAbs Therapeutics Systematic Risk
Y MAbs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Y MAbs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Y mAbs Therapeutics correlated with the market. If Beta is less than 0 Y MAbs generally moves in the opposite direction as compared to the market. If Y MAbs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Y mAbs Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Y MAbs is generally in the same direction as the market. If Beta > 1 Y MAbs moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Y MAbs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Y MAbs' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Y MAbs growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Y MAbs December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Y MAbs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Y mAbs Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Y mAbs Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing YMAB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Y MAbs's daily price indicators and compare them against related drivers.
Information Ratio | (0.12) | |||
Maximum Drawdown | 22.06 | |||
Value At Risk | (5.31) | |||
Potential Upside | 5.0 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |